MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.570
+0.160
+4.69%
After Hours: 3.570 0 0.00% 16:00 05/20 EDT
OPEN
3.480
PREV CLOSE
3.410
HIGH
3.570
LOW
3.240
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
25.06
52 WEEK LOW
3.220
MARKET CAP
329.26M
P/E (TTM)
-3.6899
1D
5D
1M
3M
1Y
5Y
Seres Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter.
Benzinga · 3d ago
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which i...
Business Wire · 05/10 11:00
Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Slashed This Year's Revenue Estimates By 59%
Market forces rained on the parade of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders today, when the analysts...
Simply Wall St. · 05/05 13:30
BRIEF-Seres Therapeutics Reports First Quarter 2022 Results
reuters.com · 05/04 12:53
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:25
Recap: Seres Therapeutics Q1 Earnings
  Seres Therapeutics (NASDAQ:MCRB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 11:27
Seres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49M
Seres Therapeutics press release (NASDAQ:MCRB): Q1 GAAP EPS of -$0.61 misses by $0.09. Revenue of $1.49M (-74.0% Y/Y).
Seekingalpha · 05/04 11:11
Seres Therapeutics Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $1.49M Down From $5.72M YoY
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 56.41 percent decrease over losses of $(0.39) per share
Benzinga · 05/04 11:05
More
No Data
Learn about the latest financial forecast of MCRB. Analyze the recent business situations of Seres Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
44.44%Buy
11.11%Hold
11.11%Under-perform
0.00%Sell
Analyst Price Target
The average MCRB stock price target is 16.50 with a high estimate of 32.00 and a low estimate of 4.000.
High32.00
Average16.50
Low4.000
Current 3.570
EPS
Actual
Estimate
-0.31-0.010.300.60
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 170
Institutional Holdings: 76.62M
% Owned: 83.07%
Shares Outstanding: 92.23M
TypeInstitutionsShares
Increased
45
3.62M
New
7
497.77K
Decreased
53
5.17M
Sold Out
23
693.31K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Berenson
President/Chief Executive Officer/Director
Eric Shaff
Chief Financial Officer/Executive Vice President
David Arkowitz
Chief Human Resource Officer/Executive Vice President
Paula Cloghessy
Executive Vice President/Chief Technology Officer
John Aunins
Executive Vice President/Chief Technology Officer
David Ege
Executive Vice President/Chief Scientific Officer
Matthew Henn
Executive Vice President/Secretary
Thomas DesRosier
Executive Vice President
Lisa von Moltke
Executive Vice President
Teresa Young
Senior Vice President - Finance/Chief Accounting Officer
Marcus Chapman
Independent Director
Dennis Ausiello
Independent Director
Gregory Behar
Independent Director
Paul Biondi
Independent Director
Willard Dere
Independent Director
Kurt Graves
Independent Director
Richard Kender
Independent Director
Meryl Zausner
No Data
No Data
About MCRB
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.